UAE Approves Ruxolitinib for Polycythemia
The Emirates Authority for Pharmaceuticals has announced the approval of the medication "Mimerylo" (Ruxolitinib) for the treatment of adults with polycythemia vera, making the UAE the second country in the world to approve its use. "Mimerylo" is a treatment that reduces red blood cell levels to help control this rare blood disorder, which causes blood viscosity to increase and raises the risk of blood clots. The medication is used under medical supervision and aims to improve disease management and patients' quality of life, while also expanding available treatment options for rare diseases in the UAE.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)